Skip to main content

Table 1 Summary of simulations: variables and levels

From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Variable Details and levels simulated
Vaccination: infant cohort (EPI cohort) 6, 10, 14 weeks; booster at 21 months
Vaccination: children cohort (5–17 months cohort) Ages between 5–17 months first dose, and for 3rd dose 8–20 months; booster at 26–38 months
Model variants [8] 1. R0000 Base model
2. R0068 Heterogeneity in transmission: within-host variability
3. R0131 Immunity decay in effective cumulative exposure
4. R0132 Immunity decay in immune proxies
5. R0133 Immunity decay in both immune proxies and effective cumulative exposure
6. R0670 Heterogeneity in susceptibility to co-morbidity
EIR 0.1a, 1, 2, 4, 8, 16, 64, 256
Access to uncomplicated case management (%)b 0, 5, 40
Access inpatient care for severe cases (%)c 0, 100
Vaccination coveraged 0, 100
Initial efficacy against infection of third dose (%) 30, 60, 80, 100
Half-life (years) 0.5, 1, 3, 5
Initial efficacy against infection of boosting dose (%)e Third dose efficacy, 30, 100
Weibull decay shape parameter (k) k = 1 (exponential)
k = 0.5 (bi-phasic, quick decay followed by slow decay)
k = 3 (slow decay, followed by quick decay)
  1. aEIR of 0.1 was not simulated, predictions for this level are taken as 10 % of EIR 1
  2. bProbability of access to treatment for uncomplicated disease during a 5-day period (for mapping onto rates of access estimated from survey data see [6, 31]
  3. cProbability of access to hospital care (or equivalent) for severe disease during any 5-day period
  4. dFor each of the four delivery schedules
  5. eThis represents the absolute efficacy against infection achieved by the addition of a booster doses and not a percentage of the third dose